Malignant Glioma - Market Insights, Epidemiology and Market Forecast - 2025

Publisher Name :
Date: 01-Nov-2017
No. of pages: 70
Price : Single User: US $ 5750  US $ 4600 Corporate User: US $ 17250  US $ 10350
This report is available at 20% Discount for Single User License and 40% Discount for Corporate Users License till 31 December 2017. To avail discount please contact at +1-888-391-5441 / sales@rnrmarketresearch.com.
Delivery of the Report will take 2-3 working days once order is placed.

DelveInsight's "Malignant Glioma - Market Insights, Epidemiology and Market Forecast - 2025" report provides an overview of the disease and in depth research related to Malignant Glioma for the 7MM (United States, Germany, France, Italy, Spain and UK) for the study period undertaken from 2015-2025. This report provides understanding of the patients affected, diagnosed patterns, treatment trends, unmet medical needs and current developments for Malignant Glioma . It enables understanding of the historical and forecasted epidemiological data for the diagnosed prevalent cases of Malignant Glioma for 7 major markets.

The market outlook also provides understanding of country specific revenue and share by analyzing performance of the current therapies and thorough potential uptake of new products. Additionally, the Report highlights the frontrunners, the drivers and barriers for the Malignant Glioma market, as well as treatment algorithm, current treatments & advancements are included.The chapters including marketed products highlights the advantages and disadvantages associated with therapies associated with Malignant Glioma , providing an in-depth analysis of emerging therapies which will create an impact through their launch.

According to DelveInsight, the forecasted patient population of Malignant Glioma for the year 2025 will be XX, increasing at a CAGR of XX% from 2015 to 2025 and the Malignant Glioma 7MM market size is estimated to be USD XX by 2025.The DelveInsight Report will help in enhanced understanding of the Malignant Glioma market from inside out, with transparency into the calculated patient forecasting data and estimated market size.

Key Coverage

  • Understanding historical and forecasted epidemiological data for Malignant Glioma covering 7MM from 2015-2025.

  • Segment level epidemiology and market split for Malignant Glioma .

  • The thorough assessment of competitors, market, current trends & treatments along with upcoming treatments for Malignant Glioma .

  • The Report also covers the market size for 7MM (United States, EU 5 (Germany, Spain, Italy, France and United Kingdom) and Japan) from 2015-2025 and detailed historical and forecasted Malignant Glioma market trends.

  • Thorough market distribution based on market share for Malignant Glioma .

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Malignant Glioma market.

  • To understand the future market competition in the Malignant Glioma market and Insightful review of the key market drivers and barriers.

  • Organize sales and marketing efforts by identifying the best opportunities for Malignant Glioma in US, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan.

  • Identification of strong upcoming players in market will help in devising strategies that will help in getting ahead of competitors.

This report is available at 20% Discount for Single User License and 40% Discount for Corporate Users License till 31 December 2017. To avail discount please contact at +1-888-391-5441 / sales@rnrmarketresearch.com.

Malignant Glioma - Market Insights, Epidemiology and Market Forecast - 2025

Table of Contents

1. Report Introduction

2. Malignant Glioma Market Overview at a Glance
2.1. Total Market Share Distribution of Malignant Glioma for 7 MM in 2016
2.2. Total Market Share Distribution of Malignant Glioma for 7 MM in 2025

3. Malignant Glioma
3.1.1. Overview
3.1.2. Symptoms
3.1.3. Pathophysiology
3.1.4. Staging
3.1.5. Diagnosis
3.1.6. Treatment

4. Epidemiology and Patient Population
4.1.1. United States
4.1.1.1. Diagnosed Cases of Malignant Glioma in United States
4.1.2. Germany
4.1.2.1. Diagnosed Cases of Malignant Glioma in Germany
4.1.3. France
4.1.3.1. Diagnosed Cases of Malignant Glioma in France
4.1.4. Italy
4.1.4.1. Diagnosed Cases of Malignant Glioma in Italy
4.1.5. Spain
4.1.5.1. Diagnosed Cases of Malignant Glioma in Spain
4.1.6. United Kingdom
4.1.6.1. Diagnosed Cases of Malignant Glioma in United Kingdom

5. Treatment Algorithm
5.1.1. Treatment Guidelines/Practices

6. Marketed Drugs for Malignant Glioma
6.1. Drug 1: Company A
6.1.1. Drug Description
6.1.2. Mechanism of Action
6.1.3. Regulatory Milestones
6.1.4. Advantages & Disadvantages
6.1.5. Safety and Efficacy
6.1.6. Product Profile
6.1.7. Patent Status
6.2. Drug 2: Company B
6.2.1. Drug Description
6.2.2. Mechanism of Action
6.2.3. Regulatory Milestones
6.2.4. Advantages & Disadvantages
6.2.5. Safety and Efficacy
6.2.6. Product Profile
6.2.7. Patent Status

7. Emerging Therapies
7.1. Drug 3: Company C
7.1.1. Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Product Profile
7.1.5. Launch Date
7.1.6. Clinical Development
7.1.7. Clinical Pipeline Activity
7.1.8. Ongoing Trials Information
7.1.9. Clinical Trial by Phase
7.2. Drug 4: Company B
7.2.1. Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Product Profile
7.2.5. Launch Date
7.2.6. Clinical Development
7.2.7. Clinical Pipeline Activity
7.2.8. Ongoing Trials Information
7.2.9. Clinical Trial by Phase

8. Overview of Total Malignant Glioma Market (2016 & 2025)

9. Malignant Glioma : Country-Wise Market Analysis
9.1. United States
9.1.1. Historical Market Size (2015-2016)
9.1.2. Forecasted Market Size (2017-2025)
9.2. Germany Market Size
9.2.1. Historical Market Size (2015-2016)
9.2.2. Forecasted Market Size (2017-2025)
9.3. France Market Size
9.3.1. Historical Market Size (2015-2016)
9.3.2. Forecasted Market Size (2017-2025)
9.4. United Kingdom Market Size
9.4.1. Historical Market Size (2015-2016)
9.4.2. Forecasted Market Size (2017-2025)
9.5. Spain Market Size
9.5.1. Historical Market Size (2015-2016)
9.5.2. Forecasted Market Size (2017-2025)
9.6. Italy Market Size
9.6.1. Historical Market Size (2015-2016)
9.6.2. Forecasted Market Size (2017-2025)
9.7. Japan Market Size
9.7.1. Historical Market Size (2015-2016)
9.7.2. Forecasted Market Size (2017-2025)

10. Market Drivers

11. Market Restraints

12. Appendix

13. Report Methodology

14. Consulting Services

15. Disclaimer

16. About DelveInsight

List of Tables

Table 1: Diagnosed Cases Malignant Glioma in United States (2015-2025)
Table 2: Diagnosed Cases Malignant Glioma in Germany (2015-2025)
Table 3: Diagnosed Cases Malignant Glioma in France (2015-2025)
Table 4: Diagnosed Cases Malignant Glioma in United Kingdom (2015-2025)
Table 5: Diagnosed Cases Malignant Glioma in Spain (2015-2025)
Table 6: Diagnosed Cases Malignant Glioma in Italy (2015-2025)
Table 7: Diagnosed Cases Malignant Glioma in Japan (2015-2025)
Table 8: List of Marketed Drugs for Malignant Glioma
Table 9: List of Pipeline Phase III Drugs for Malignant Glioma
Table 10: Drug 1, Clinical Trials by Zone, 2017
Table 11: Clinical Trials by Trial status, 2017
Table 12: Drug 2, Clinical Trials by Zone, 2017
Table 13: Clinical Trials by Trial status, 2017
Table 14: Drug 3, Clinical Trials by Zone, 2017
Table 15: Clinical Trials by Trial status, 2017
Table 16: United States Market Size of Malignant Glioma in USD, Million (2015-2025)
Table 17: Germany Market Size of Malignant Glioma in USD, Million (2015-2025)
Table 18: France Market Size of Malignant Glioma in USD, Million (2015-2025)
Table 19: United Kingdom Market Size of Malignant Glioma in USD, Million (2015-2025)
Table 20: Spain Market Size of Malignant Glioma in USD, Million (2015-2025)
Table 21: Italy Market Size of Malignant Glioma in USD, Million (2015-2025)
Table 22: Japan Market Size of Malignant Glioma in USD, Million (2015-2025)

List of Figures

Figure 1: Diagnosed Cases Malignant Glioma in United States (2015-2025)
Figure 2: Diagnosed Cases Malignant Glioma in Germany (2015-2025)
Figure 3: Diagnosed Cases Malignant Glioma in France (2015-2025)
Figure 4: Diagnosed Cases Malignant Glioma in United Kingdom (2015-2025)
Figure 5: Diagnosed Cases Malignant Glioma in Spain (2015-2025)
Figure 6: Diagnosed Cases Malignant Glioma in Italy (2015-2025)
Figure 7: Diagnosed Cases Malignant Glioma in Japan (2015-2025)
Figure 8: List of Marketed Drugs for Malignant Glioma
Figure 9: List of Pipeline Phase III Drugs for Malignant Glioma
Figure 10: Drug 1, Clinical Trials by Zone (%), 2017
Figure 11: Clinical Trials by Trial status, 2017
Figure 12: Drug 2, Clinical Trials by Zone (%), 2017
Figure 13: Clinical Trials by Trial status, 2017
Figure 14: Drug 3, Clinical Trials by Zone (%), 2017
Figure 15: Clinical Trials by Trial status, 2017
Figure 16: United States Market Size of Malignant Glioma in USD, Million (2015-2025)
Figure 17: Germany Market Size of Malignant Glioma in USD, Million (2015-2025)
Figure 18: France Market Size of Malignant Glioma in USD, Million (2015-2025)
Figure 19: United Kingdom Market Size of Malignant Glioma in USD, Million (2015-2025)
Figure 20: Spain Market Size of Malignant Glioma in USD, Million (2015-2025)
Figure 21: Italy Market Size of Malignant Glioma in USD, Million (2015-2025)
Figure 22: Japan Market Size of Malignant Glioma in USD, Million (2015-2025)
  • Global Cancer Gene Therapy Market Research Report 2017
    Published: 04-Dec-2017        Price: US 2900 Onwards        Pages: 120
    In this report, the global Cancer Gene Therapy market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Cancer Gene Therapy in these regions, from 2012 to 2022 (forecast), covering - North America - Europe - China......
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2017
    Published: 30-Nov-2017        Price: US 2000 Onwards        Pages: 524
    Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2017, provides an overview of the Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) pipeline landscape. Chronic myeloid leukemia (CML), also known as chronic myelogenous leukemia, is a type of cancer that starts in the blood-forming cells of the bone marrow and invades......
  • Ewing Sarcoma - Pipeline Review, H2 2017
    Published: 30-Nov-2017        Price: US 2000 Onwards        Pages: 326
    Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ewing Sarcoma - Pipeline Review, H2 2017, provides an overview of the Ewing Sarcoma (Oncology) pipeline landscape. Ewing's sarcoma is a primary bone cancer that affects mainly children and adolescents. Ewing's sarcoma can occur any time during childhood and young adulthood, but usually develops during puberty, when bones are growing rapidly. There are few symptoms. The ......
  • Meningioma - Pipeline Review, H2 2017
    Published: 30-Nov-2017        Price: US 2000 Onwards        Pages: 229
    Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Meningioma - Pipeline Review, H2 2017, provides an overview of the Meningioma (Oncology) pipeline landscape. A meningioma is a type of tumor that develops from the meninges, the membrane that surrounds the brain and spinal cord. There are three layers of meninges, called the dura mater, arachnoid and pia mater. Most meningiomas (90%) are categorized as benign tumors, wi......
  • Gallbladder Cancer - Pipeline Review, H2 2017
    Published: 30-Nov-2017        Price: US 2000 Onwards        Pages: 179
    Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gallbladder Cancer - Pipeline Review, H2 2017, provides an overview of the Gallbladder Cancer (Oncology) pipeline landscape. Gallbladder cancer is a cancer that starts in the gallbladder. Symptoms include abdominal pain, nausea and/or vomiting, jaundice, loss of appetite, fever, itchy skin, dark urine and weight loss. Risk factors include overweight, age, family history......
  • Hepatocellular Carcinoma - Pipeline Review, H2 2017
    Published: 30-Nov-2017        Price: US 2500 Onwards        Pages: 1120
    Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hepatocellular Carcinoma - Pipeline Review, H2 2017, provides an overview of the Hepatocellular Carcinoma (Oncology) pipeline landscape. Hepatocellular carcinoma (HCC) is a type of cancer originates from a liver cell (hepatocyte) which becomes cancerous. This type of cancer occurs more often in men than women. Symptoms include abdominal pain or tenderness, especially in......
  • Cervical Cancer - Pipeline Review, H2 2017
    Published: 30-Nov-2017        Price: US 2000 Onwards        Pages: 674
    Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cervical Cancer - Pipeline Review, H2 2017, provides an overview of the Cervical Cancer (Oncology) pipeline landscape. Cervical intraepithelial neoplasia (CIN), also known as cervical dysplasia is characterized by abnormal appearance of cells on the surface of the cervix. Cervical dysplasia usually occurs in women aging twenty five to thirty five. Most cases of cervical......
  • Vaginal Cancer - Pipeline Review, H2 2017
    Published: 30-Nov-2017        Price: US 2000 Onwards        Pages: 92
    Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Vaginal Cancer - Pipeline Review, H2 2017, provides an overview of the Vaginal Cancer (Oncology) pipeline landscape. Vaginal cancer is a rare cancer that occurs in vagina. Symptoms includes watery vaginal discharge, a lump or mass in vagina, painful urination, constipation and pelvic pain, vaginal bleeding. Risk factors include age, Smoking, HIV infection and vaginal in......
  • Vulvar Cancer - Pipeline Review, H2 2017
    Published: 30-Nov-2017        Price: US 2000 Onwards        Pages: 92
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Vulvar Cancer - Pipeline Review, H2 2017, provides an overview of the Vulvar Cancer (Oncology) pipeline landscape. Vulvar cancer is a rare type of cancer. It forms in a woman's external genitals, called the vulva. The cancer usually develops slowly over several years. First, precancerous cells grow on vulvar skin. This is called vulvar intraepithelial neoplasia (VIN), or dysplasia. Not all VIN cases tu......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs